High-Dose Donepezil (23 mg/day) for the Treatment of Moderate and Severe Alzheimer's Disease: Drug Profile and Clinical Guidelines

Jeffrey L. Cummings, David Geldmacher, Martin Farlow, Marwan Sabbagh, Daniel Christensen, Peter Betz

Research output: Contribution to journalArticle

29 Citations (Scopus)

Abstract

Summary: To provide healthcare professionals with a comprehensive assessment of donepezil 23 mg and its role in treating Alzheimer's disease (AD), the Donepezil 23 mg Expert Working Group (EWG) convened in June 2011 to critically evaluate the clinical trial database for this higher dose formulation and the members' clinical experience with its use. Discussions were based on a large, 6-month, phase 3 clinical trial in patients with moderate to severe AD that compared continuing donepezil 10 mg/day versus switching to 23 mg/day. In this trial, donepezil 23 mg/day demonstrated significantly greater cognitive benefits (mean change in Severe Impairment Battery score, 2.11 points; P <0.001). Prespecified analyses showed that benefits were significant irrespective of concomitant memantine use. The EWG considered integrating these new data into clinical practice approaches. Dementia severity, tolerability of the 10 mg dose, and need for additional therapy were key selection criteria, as was monitoring of gastrointestinal side effects, as consideration of titration strategies is an important aspect of implementation. The EWG concluded that donepezil 23 mg is an efficacious therapy for moderate to severe AD, with or without concomitant memantine, extending the treatment opportunities available to manage moderate to severe AD dementia. EWG guidelines offer assistance to clinicians in choosing and implementing treatment options.

Original languageEnglish (US)
Pages (from-to)294-301
Number of pages8
JournalCNS Neuroscience and Therapeutics
Volume19
Issue number5
DOIs
StatePublished - May 2013
Externally publishedYes

Fingerprint

Alzheimer Disease
Guidelines
Memantine
Pharmaceutical Preparations
Therapeutics
Phase III Clinical Trials
Patient Selection
Dementia
donepezil
Clinical Trials
Databases
Delivery of Health Care

Keywords

  • Alzheimer's disease
  • Donepezil
  • Efficacy
  • Moderate to severe
  • Safety
  • Tolerability

ASJC Scopus subject areas

  • Pharmacology (medical)
  • Physiology (medical)
  • Psychiatry and Mental health
  • Pharmacology
  • Medicine(all)

Cite this

High-Dose Donepezil (23 mg/day) for the Treatment of Moderate and Severe Alzheimer's Disease : Drug Profile and Clinical Guidelines. / Cummings, Jeffrey L.; Geldmacher, David; Farlow, Martin; Sabbagh, Marwan; Christensen, Daniel; Betz, Peter.

In: CNS Neuroscience and Therapeutics, Vol. 19, No. 5, 05.2013, p. 294-301.

Research output: Contribution to journalArticle

Cummings, Jeffrey L. ; Geldmacher, David ; Farlow, Martin ; Sabbagh, Marwan ; Christensen, Daniel ; Betz, Peter. / High-Dose Donepezil (23 mg/day) for the Treatment of Moderate and Severe Alzheimer's Disease : Drug Profile and Clinical Guidelines. In: CNS Neuroscience and Therapeutics. 2013 ; Vol. 19, No. 5. pp. 294-301.
@article{6ca9e59fece84b51875b84becdf97e8a,
title = "High-Dose Donepezil (23 mg/day) for the Treatment of Moderate and Severe Alzheimer's Disease: Drug Profile and Clinical Guidelines",
abstract = "Summary: To provide healthcare professionals with a comprehensive assessment of donepezil 23 mg and its role in treating Alzheimer's disease (AD), the Donepezil 23 mg Expert Working Group (EWG) convened in June 2011 to critically evaluate the clinical trial database for this higher dose formulation and the members' clinical experience with its use. Discussions were based on a large, 6-month, phase 3 clinical trial in patients with moderate to severe AD that compared continuing donepezil 10 mg/day versus switching to 23 mg/day. In this trial, donepezil 23 mg/day demonstrated significantly greater cognitive benefits (mean change in Severe Impairment Battery score, 2.11 points; P <0.001). Prespecified analyses showed that benefits were significant irrespective of concomitant memantine use. The EWG considered integrating these new data into clinical practice approaches. Dementia severity, tolerability of the 10 mg dose, and need for additional therapy were key selection criteria, as was monitoring of gastrointestinal side effects, as consideration of titration strategies is an important aspect of implementation. The EWG concluded that donepezil 23 mg is an efficacious therapy for moderate to severe AD, with or without concomitant memantine, extending the treatment opportunities available to manage moderate to severe AD dementia. EWG guidelines offer assistance to clinicians in choosing and implementing treatment options.",
keywords = "Alzheimer's disease, Donepezil, Efficacy, Moderate to severe, Safety, Tolerability",
author = "Cummings, {Jeffrey L.} and David Geldmacher and Martin Farlow and Marwan Sabbagh and Daniel Christensen and Peter Betz",
year = "2013",
month = "5",
doi = "10.1111/cns.12076",
language = "English (US)",
volume = "19",
pages = "294--301",
journal = "CNS Neuroscience and Therapeutics",
issn = "1755-5930",
publisher = "Wiley-Blackwell",
number = "5",

}

TY - JOUR

T1 - High-Dose Donepezil (23 mg/day) for the Treatment of Moderate and Severe Alzheimer's Disease

T2 - Drug Profile and Clinical Guidelines

AU - Cummings, Jeffrey L.

AU - Geldmacher, David

AU - Farlow, Martin

AU - Sabbagh, Marwan

AU - Christensen, Daniel

AU - Betz, Peter

PY - 2013/5

Y1 - 2013/5

N2 - Summary: To provide healthcare professionals with a comprehensive assessment of donepezil 23 mg and its role in treating Alzheimer's disease (AD), the Donepezil 23 mg Expert Working Group (EWG) convened in June 2011 to critically evaluate the clinical trial database for this higher dose formulation and the members' clinical experience with its use. Discussions were based on a large, 6-month, phase 3 clinical trial in patients with moderate to severe AD that compared continuing donepezil 10 mg/day versus switching to 23 mg/day. In this trial, donepezil 23 mg/day demonstrated significantly greater cognitive benefits (mean change in Severe Impairment Battery score, 2.11 points; P <0.001). Prespecified analyses showed that benefits were significant irrespective of concomitant memantine use. The EWG considered integrating these new data into clinical practice approaches. Dementia severity, tolerability of the 10 mg dose, and need for additional therapy were key selection criteria, as was monitoring of gastrointestinal side effects, as consideration of titration strategies is an important aspect of implementation. The EWG concluded that donepezil 23 mg is an efficacious therapy for moderate to severe AD, with or without concomitant memantine, extending the treatment opportunities available to manage moderate to severe AD dementia. EWG guidelines offer assistance to clinicians in choosing and implementing treatment options.

AB - Summary: To provide healthcare professionals with a comprehensive assessment of donepezil 23 mg and its role in treating Alzheimer's disease (AD), the Donepezil 23 mg Expert Working Group (EWG) convened in June 2011 to critically evaluate the clinical trial database for this higher dose formulation and the members' clinical experience with its use. Discussions were based on a large, 6-month, phase 3 clinical trial in patients with moderate to severe AD that compared continuing donepezil 10 mg/day versus switching to 23 mg/day. In this trial, donepezil 23 mg/day demonstrated significantly greater cognitive benefits (mean change in Severe Impairment Battery score, 2.11 points; P <0.001). Prespecified analyses showed that benefits were significant irrespective of concomitant memantine use. The EWG considered integrating these new data into clinical practice approaches. Dementia severity, tolerability of the 10 mg dose, and need for additional therapy were key selection criteria, as was monitoring of gastrointestinal side effects, as consideration of titration strategies is an important aspect of implementation. The EWG concluded that donepezil 23 mg is an efficacious therapy for moderate to severe AD, with or without concomitant memantine, extending the treatment opportunities available to manage moderate to severe AD dementia. EWG guidelines offer assistance to clinicians in choosing and implementing treatment options.

KW - Alzheimer's disease

KW - Donepezil

KW - Efficacy

KW - Moderate to severe

KW - Safety

KW - Tolerability

UR - http://www.scopus.com/inward/record.url?scp=84876789305&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84876789305&partnerID=8YFLogxK

U2 - 10.1111/cns.12076

DO - 10.1111/cns.12076

M3 - Article

C2 - 23462265

AN - SCOPUS:84876789305

VL - 19

SP - 294

EP - 301

JO - CNS Neuroscience and Therapeutics

JF - CNS Neuroscience and Therapeutics

SN - 1755-5930

IS - 5

ER -